NxStage Medical Inc. (NXTM) SVP Winifred L. Swan Sells 3,000 Shares of Stock
NxStage Medical Inc. (NASDAQ:NXTM) SVP Winifred L. Swan sold 3,000 shares of the firm’s stock in a transaction dated Tuesday, November 22nd. The stock was sold at an average price of $25.51, for a total value of $76,530.00. Following the sale, the senior vice president now directly owns 14,973 shares in the company, valued at approximately $381,961.23. The sale was disclosed in a document filed with the SEC, which is accessible through this link.
NxStage Medical Inc. (NASDAQ:NXTM) traded down 0.33% on Wednesday, hitting $24.41. The stock had a trading volume of 151,509 shares. NxStage Medical Inc. has a 12-month low of $13.49 and a 12-month high of $26.83. The company’s 50 day moving average price is $24.30 and its 200-day moving average price is $22.50. The company’s market cap is $1.58 billion.
Several hedge funds have recently made changes to their positions in NXTM. Teacher Retirement System of Texas boosted its stake in NxStage Medical by 35.5% in the second quarter. Teacher Retirement System of Texas now owns 8,958 shares of the medical device company’s stock valued at $194,000 after buying an additional 2,347 shares in the last quarter. Bank of Montreal Can acquired a new stake in NxStage Medical during the second quarter valued at approximately $14,911,000. Prudential Financial Inc. boosted its stake in NxStage Medical by 54.4% in the second quarter. Prudential Financial Inc. now owns 501,096 shares of the medical device company’s stock valued at $10,863,000 after buying an additional 176,510 shares in the last quarter. Nisa Investment Advisors LLC boosted its stake in NxStage Medical by 1,418.2% in the second quarter. Nisa Investment Advisors LLC now owns 16,700 shares of the medical device company’s stock valued at $362,000 after buying an additional 15,600 shares in the last quarter. Finally, GSA Capital Partners LLP boosted its stake in NxStage Medical by 98.4% in the second quarter. GSA Capital Partners LLP now owns 40,426 shares of the medical device company’s stock valued at $876,000 after buying an additional 20,046 shares in the last quarter. Institutional investors and hedge funds own 98.86% of the company’s stock.
Several equities research analysts have recently weighed in on the company. Zacks Investment Research lowered NxStage Medical from a “buy” rating to a “hold” rating in a research report on Wednesday, August 10th. Canaccord Genuity reaffirmed a “buy” rating and set a $28.00 price target on shares of NxStage Medical in a research report on Thursday, November 3rd. BTIG Research reaffirmed a “buy” rating and set a $29.00 price target on shares of NxStage Medical in a research report on Sunday, August 7th. Jefferies Group lifted their price target on NxStage Medical from $24.00 to $27.00 and gave the stock a “buy” rating in a research report on Friday, August 5th. Finally, Northland Securities set a $25.00 price target on NxStage Medical and gave the stock a “buy” rating in a research report on Thursday, September 15th. One analyst has rated the stock with a sell rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $25.67.
COPYRIGHT VIOLATION WARNING: This piece of content was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of US & international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2016/11/23/nxstage-medical-inc-nxtm-svp-winifred-l-swan-sells-3000-shares-of-stock.html.
About NxStage Medical
NxStage Medical, Inc is a medical technology company. The Company is engaged in the development, manufacturing and marketing of products and services for patients suffering from chronic or acute kidney failure. The Company operates through three segments: System One, In-Center and Services. It offers its products and services to various markets, such as home, critical care and in-center.
Receive News & Stock Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related stocks with our FREE daily email newsletter.